Barclays lowered the firm’s price target on Agilent (A) to $115 from $138 and keeps an Equal Weight rating on the shares as part of a Q1 earnings preview for life science tools and diagnostics group. Tools are still defensive, but less so than in the past given the threat of the pharma-specific tariffs potentially causing another round of budget cuts, the analyst tells investors in a research note. Barclays also downgraded the contract research organizations on lower visibility.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on A:
- Agilent placed on ‘positive catalyst watch’ at Citi
- Agilent, Seagate, Dollar Tree, Coupang, Appian: Insider Moves Unveiled
- Agilent xCELLigence RTCA instrumentation applied in recent FDA approval
- Best Buy, Las Vegas Sands, Globalstar, Opko Health, Agilent: Stock Moves Unveiled
- Agilent’s PD-L1 IHC 28-8 pharmDx gets added indications under EU IVDR1 for NSLC